Expression of CD16ζ in NK Cells of B-cell Non-Hodgkin's Lymphoma Patients and In Vitro Killing Effect of Rituximab Combined Lymphokine-activated Killer Cells on B-NHL Cells
BACKGROUND & OBJECTIVE: Natural killer (NK) cells are the main effector of antibody-dependent cellular cytotoxicity (ADCC). The activation disorder of NK cells in cancer patients may affect the treatment effect of monoclonal antibody. Reversing the dysfunction of signal transduction of CD16ζ chain in NK cells and combining lymphokine-activated killer (LAK) cells with rituximab may give rise to synergistic effect. This study was to find out whether the activation disorder of NK cells exist in B-cell non-Hodg...